E.F. ISKHAKOVA¹, V.N. MUKHAMADIEVA¹, E.V. DYAKOVA², N.G. SHAMSUTDINOVA¹, R.Z. ABDRAKIPOV², E.V. SUKHORUKOVA², S.A. LAPSHINA¹, D.I. ABDULGANIEVA^1, 2

 ¹Kazan State Medical University, Kazan

²Republican Clinical Hospital of the MHof RT, Kazan

 Contact details:

Iskhakova E.F. — resident of the Department of Hospital Therapy

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-912-872-50-20, e-mail: elmiraiskhakova@yandex.ru

Today the issues related to the management of patients with immunoinflammatory rheumatic diseases and the new coronavirus infection (NCI), despite numerous studies, remain open for discussion. Due to the rare occurrence of systemic lupus erythematosus (SLE), publications devoted to the study of the characteristics of the course of COVID-19 in this group of patients are limited to a description of a small series of cases. The article provides information on possible risk factors for severe NCI in patients with SLE. The article presents our own clinical observation of a patient with a long history of SLE who had bilateral pneumonia caused by SARS-CoV-2, against the background of low activity of the underlying disease, achieved by taking genetically engineered biologic drugs. NCI was accompanied by rapid progression of lung damage, prolonged persistence of fever, respiratory failure, and asthenic syndrome. Further monitoring of the patient’s condition is required.

Key words: COVID-19, systemic lupus erythematosus, belimumab, rituximab.

REFERENCES

1. Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19). Versiya 10 (08.02.2021) [Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 10 (02/08/2021)]. P. 6.
2. Gupta A., Madhavan M.V., Sehgal K. et al. Extrapulmonary manifestations of COVID-19. Nat. Med., 2020, vol. 26, pp. 1017–1032.
3. Nasonov E.L., Beketova T.V., Reshetnyak T.M. et al. Coronavirus disease 2019 (COVID-19) and immunoinflammatory rheumatic diseases: at the crossroads of thrombus inflammation and autoimmunity. Nauchno-prakticheskaya revmatologiya, 2020, vol. 58, no. 4, pp. 353–367 (in Russ.).
4. Sawalha A.H., Zhao M., Coit P., Lu Q. Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin. Immunol., 2020, vol. 215, 108410.
5. Mason A., Rose E., Edwards C.J. Clinical management ofLupus patients during the COVID-19 pandemic. Lupus, 2020, vol. 29 (13), pp. 1661–1672.
6. Nasonov E.L., Lila A.M., Mazurov V.I. et al. Koronavirusnaya bolezn’ 2019 (COVID-19) i immunovospalitel’nye (autoimmunnye) revmaticheskie zabolevaniya. Proekt rekomendatsiy Obshcherossiyskoy obshchestvennoy organizatsii «Assotsiatsiya revmatologov Rossii» [], available at: https://rheumatolog.su/news/koronavirusnaya-bolezn-2019-COVID-19-i-immunovospalitelnye-autoimmunnye-revmaticheskie-zabolevaniya/ (accessed on: 13.03.2021).
7. EULAR COVID-19 database, available at: https://www.eular.org/eular_covid19_database.cfm (accessed on: 09.03.2021).
8. The COVID-19 Global Rheumatology Alliance Global Registry, available at: https://rheum-covid.org/updates/combined-data.html (accessed on: 09.03.2021).
9. Gianfrancesco M., Hyrich K.L., Al-Adelyet al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis., 2020, vol. 79, pp. 859–866.
10. Mathian A., Mahevas M., Rohmer J. et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann. Rheum. Dis., 2020, vol. 79, pp. 837–839.
11. Gartshteyn Y., Askanase A.D., Schmidt N.M. et al. COVID-19 and systemic lupus erythematosus: a case series. Lancet Rheumatol., 2020, vol. 2 (8), pp. 452–454.
12. Betrains A., Godinas L., Woei‐A‐Jin et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br. J. Haematol., 2021, vol. 192 (6), pp. 1100–1105.